ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Belite Bio Inc

Belite Bio Inc (BLTE)

47.99
-0.13
( -0.27% )
Updated: 11:16:53

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
47.99
Bid
47.90
Ask
48.20
Volume
4,433
47.54 Day's Range 47.99
0.00 52 Week Range 0.00
Market Cap
Previous Close
48.12
Open
47.81
Last Trade
1
@
47.91
Last Trade Time
11:22:43
Financial Volume
$ 212,130
VWAP
47.8524
Average Volume (3m)
-
Shares Outstanding
29,149,444
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Belite Bio Inc

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressiv... Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Grand Cayman, Cym
Founded
1970
Belite Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BLTE. The last closing price for Belite Bio was $48.12. Over the last year, Belite Bio shares have traded in a share price range of $ 0.00 to $ 0.00.

Belite Bio currently has 29,149,444 shares outstanding. The market capitalization of Belite Bio is $1.40 billion.

BLTE Latest News

Belite Bio to Present at the JonesHealthcare Seaside Summit

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry...

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.955
(82.71%)
137.18M
PBMPsyence Biomedical Ltd
$ 0.655
(67.35%)
65.44M
SLRXSalarius Pharmaceuticals Inc
$ 3.51
(64.02%)
17.2M
XCURExicure Inc
$ 0.5225
(30.99%)
21.24M
GSHDGoosehead Insurance Inc
$ 86.04
(30.96%)
589.05k
TWOU2U Inc
$ 1.66
(-59.71%)
3.27M
CTNTCheetah Net Supply Chain Service Inc
$ 0.2861
(-40.64%)
4.05M
KDLYKindly MD Inc
$ 1.95
(-39.44%)
552.48k
EZFLEzFill Holdings Inc
$ 3.789
(-39.13%)
103.92k
SLGLSol Gel Technologies Ltd
$ 0.44
(-34.33%)
12.85M
NVDANVIDIA Corporation
$ 115.07
(0.72%)
239.51M
POAIPredictive Oncology Inc
$ 1.955
(82.71%)
137.18M
SLNASelina Hospitality PLC
$ 0.0399
(-12.69%)
135.22M
SQQQProShares UltraPro Short QQQ
$ 9.01
(-0.55%)
127.32M
PBMPsyence Biomedical Ltd
$ 0.655
(67.35%)
65.44M

BLTE Discussion

View Posts
conix conix 2 years ago
Short Interest for BLTE--Up 30%

https://www.etfdailynews.com/2022/09/17/short-interest-in-belite-bio-inc-nasdaqblte-expands-by-30-1/
👍️0
conix conix 2 years ago
BLTE News

https://seekingalpha.com/news/3875434-blte-stock-gains-as-pivotal-trial-for-lead-asset-starts-in-us
👍️0
conix conix 2 years ago
'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

Vandana Singh

Mon, August 1, 2022

HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.

Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.

The lead drug candidate is LBS-008 (or Tinlarebant).

HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.

"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.

The analyst expects the Phase 2 portion to report 1-year data in 2H22.

Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
👍️0
conix conix 2 years ago
Belite Bio stock soars 65% in wake of strong IPO performance

May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor

IPO Initial Public Offering

Mikko Lemola/iStock via Getty Images

Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.

Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.

BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.

The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.

BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
👍️0
conix conix 2 years ago
Great news

https://www.morningstar.com/news/dow-jones/202205038965/belite-bio-shares-jump-47-after-fast-track-designation-for-lbs-008-treatment-for-stargardt-disease
👍️0

Your Recent History

Delayed Upgrade Clock